BEN LOCWIN, PHD, MBA, MS, President, Healthcare Science Advisors

Ben is a highly sought-after speaker for healthcare topics, and an author of a wide variety of scientific articles for books and magazines. He is an expert contact for the American Association of Pharmaceutical Scientists (AAPS), a committee member in the American Statistical Association (ASA), and a consultant in many industries including biological sciences, aerospace, psychological, and academic. Connect on Twitter at @BenLocwin


Healthcare Science Advisors offers advisory to hospitals, clinical healthcare settings, and the pharmaceutical industry on risk management practices, data analysis, performance measurement practices, and operational improvement.

BILL SOUCIE, Vice President of Market Access, XenoPort

Bill began his career as a peptide chemist providing him with a strong clinical base when he transitioned into the pharmaceutical industry more than 20 years ago. Since then, he has held various positions in the market access arena and has specialized in working with start-up and rebuilding organizations. He has been responsible for developing the pricing and payer strategy for the successful launch of 14 unique products across multiple therapeutic classes and has become an expert in the area of effectively communicating HEOR evidence. Utilizing insights from patients, payers, providers, and other stakeholders, Bill continues to develop creative value propositions and successful payer strategies for Vice President of Market Access.  


XenoPort, Inc. is a biopharmaceutical company focused on commercializing Horizant in the United States. XenoPort has entered into a clinical trial agreement with the NIAAA under which the NIAAA has initiated a clinical trial evaluating gabapentin enacarbil as a potential treatment for AUD. Regnite® (gabapentin enacarbil) Extended-Release Tablets are being marketed in Japan by Astellas Pharma Inc. XenoPort has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior PLC for all indications. XenoPort’s other product candidates include XP23829, a novel fumaric acid ester prodrug that is a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for patients with relapsing forms of multiple sclerosis, and XP21279, a prodrug of levodopa that is a potential treatment for patients with idiopathic Parkinson’s disease.

MATT WALLACH, Co-Founder and President, Veeva Systems

Matt Wallach has over a decade of product management, marketing, and general management experience in both traditional enterprise software and Software as a Service (SaaS). In 2007, Matt was named to the PharmaVOICE 100, which recognizes the 100 most influential people in the life sciences industry and has been published numerous times over the years in various industry trade magazines including CRM Magazine, Pharmaceutical Executive, Pharmaceutical Commerce, Pharmaceutical Representative, PharmaVOICE, and Med Ad News. Since Veeva’s inception, he has helped it grow into the leading SaaS CRM provider in the market, with six of the top 10 pharmaceutical companies as clients. Previously, he was Chief Marketing Officer at Health Market Science, a leading healthcare data services company. Matt also spent six years at Siebel Systems, where he was the General Manager of the Pharmaceuticals & Biotechnology division. Almost half of the pharmaceutical sales reps in the world use the products created during his tenure at Siebel.


Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry, delivering SaaS CRM applications built on the cloud computing model. Committed to innovation, product excellence, and customer success, Veeva has more than 375 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit


The Why of Winning Business